Retinoid Ameliorates Experimental Autoimmune Myositis, With Modulation of Th Cell Differentiation and Antibody Production In Vivo

被引:22
作者
Ohyanagi, Naho
Ishido, Miwako [2 ]
Suzuki, Fumihito
Kaneko, Kayoko
Kubota, Tetsuo
Miyasaka, Nobuyuki
Nanki, Toshihiro [1 ]
机构
[1] Tokyo Med & Dent Univ, Grad Sch, Dept Med & Rheumatol, Bunkyo Ku, Tokyo 1138519, Japan
[2] R&R Inc, Tokyo, Japan
来源
ARTHRITIS AND RHEUMATISM | 2009年 / 60卷 / 10期
关键词
EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MONONUCLEAR-CELLS; LOCAL EXPRESSION; GENE-EXPRESSION; ACID; MUSCLE; POLYMYOSITIS; DERMATOMYOSITIS; MECHANISMS; CHEMOKINES;
D O I
10.1002/art.24930
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Polymyositis and dermatomyositis are chronic inflammatory muscle diseases. Retinoids are compounds that bind to the retinoic acid binding site of retinoic acid receptors and have biologic activities similar to those of vitamin A. Recent studies indicate that retinoids promote Th2 differentiation and suppress Th1 and Th17 differentiation in vitro. The present study was undertaken to examine the effects of a synthetic retinoid, Am80, on experimental autoimmune myositis as well as on Th phenotype development and antibody production. Methods. Experimental autoimmune myositis was induced in SJL/J mice by immunization with rabbit myosin. Am80 was administered orally once daily. Its effects were evaluated by measurement of the numbers of infiltrating inflammatory cells, production of inflammatory cytokines in muscle, production of Th-specific cytokines by myosin-stimulated splenic T cells, and production of antimyosin antibodies in serum. Results. In mice with experimental autoimmune myositis, orally administered Am80 significantly reduced the number of infiltrating inflammatory cells and the expression of tumor necrosis factor a and interleukin-1 beta (IL-1 beta) in muscle. Moreover, Am80 increased production of interferon-gamma, IL-4, and IL-10, but not IL-17, by myosin-stimulated splenic T cells of mice with experimental autoimmune myositis, suggesting that it could enhance differentiation into Th1 and Th2, but not Th17, in vivo. Am80 also decreased serum levels of IgG2a and IgG2b antimyosin antibodies, but did not affect levels of IgG1 antimyosin antibodies. In addition, it suppressed chemokine expression and activator protein 1 activity in myoblasts in vitro. Conclusion. The synthetic retinoid Am80 has an inhibitory effect on experimental autoimmune myositis. It might regulate the development of Th phenotype and antibody production in vivo, in addition to its effects on cytokine and chemokine production.
引用
收藏
页码:3118 / 3127
页数:10
相关论文
共 50 条
  • [21] Artemisinin derivative TPN10466 suppresses immune cell migration and Th1/Th17 differentiation to ameliorate disease severity in experimental autoimmune encephalomyelitis
    Liu, Guangyu
    Jiang, Xiangrui
    Han, Mengyao
    Lv, Jie
    Zhuang, Wei
    Xie, Ling
    Zhang, Yan
    Wang, Chun
    Saimaier, Kaidireya
    Yang, Jingshu
    Shen, Jingshan
    Li, Ning
    Du, Changsheng
    CELLULAR IMMUNOLOGY, 2022, 373
  • [22] Infection of non-encapsulated species of Trichinella ameliorates experimental autoimmune encephalomyelitis involving suppression of Th17 and Th1 response
    Wu, Zhiliang
    Nagano, Isao
    Asano, Kazunobu
    Takahashi, Yuzo
    PARASITOLOGY RESEARCH, 2010, 107 (05) : 1173 - 1188
  • [23] Atorvastatin ameliorates experimental autoimmune neuritis by decreased Th1/Th17 cytokines and up-regulated T regulatory cells
    Li, Xiao-Li
    Dou, Ying-Chun
    Liu, Ying
    Shi, Chang-Wen
    Cao, Li-Li
    Zhang, Xiu-Qing
    Zhu, Jie
    Duan, Rui-Sheng
    CELLULAR IMMUNOLOGY, 2011, 271 (02) : 455 - 461
  • [24] Decoy receptor 3 ameliorates experimental autoimmune encephalomyelitis by directly counteracting local inflammation and downregulating Th17 cells
    Chen, Shyi-Jou
    Wang, Yen-Lin
    Kao, Jen-Hsin
    Wu, Shu-Feng
    Lo, Wen-Tsung
    Wu, Chia-Cho
    Tao, Pao-Luh
    Wang, Chih-Chien
    Chang, Deh-Ming
    Sytwu, Huey-Kang
    MOLECULAR IMMUNOLOGY, 2009, 47 (2-3) : 567 - 574
  • [25] Administration of bone marrow stromal cells ameliorates experimental autoimmune myasthenia gravis by altering the balance of Th1/Th2/Th17/Treg cell subsets through the secretion of TGF-β
    Kong, Qing-fei
    Sun, Bo
    Bai, Sha-sha
    Zhai, Dong-xu
    Wang, Guang-you
    Liu, Yu-mei
    Zhang, Shu-juan
    Li, Rui
    Zhao, Wei
    Sun, Yan-yan
    Li, Na
    Wang, Qj
    Peng, Hai-sheng
    Jin, Lian-hong
    Li, Hu-lun
    JOURNAL OF NEUROIMMUNOLOGY, 2009, 207 (1-2) : 83 - 91
  • [26] 4-Ethylguaiacol modulates neuroinflammation and Th1/Th17 differentiation to ameliorate disease severity in experimental autoimmune encephalomyelitis
    Weng, Wen-Tsan
    Kuo, Ping-Chang
    Brown, Dennis A.
    Scofield, Barbara A.
    Furnas, Destin
    Paraiso, Hallel C.
    Wang, Pei-Yu
    Yu, I-Chen
    Yen, Jui-Hung
    JOURNAL OF NEUROINFLAMMATION, 2021, 18 (01)
  • [27] A natural anti-T-cell receptor monoclonal antibody protects against experimental autoimmune encephalomyelitis
    Fernandez-Malave, Edgar
    Stark-Aroeira, Luiz
    JOURNAL OF NEUROIMMUNOLOGY, 2011, 234 (1-2) : 63 - 70
  • [28] Astilbin ameliorates experimental autoimmune myasthenia gravis by decreased Th17 cytokines and up-regulated T regulatory cells
    Meng, Qing-Fang
    Zhang, Zheng
    Wang, Yan-Jun
    Chen, Wei
    Li, Fei-Fei
    Yue, Long-Tao
    Zhang, Chang-Jun
    Li, Heng
    Zhang, Min
    Wang, Cong-Cong
    Zhang, Peng
    Chen, Hui
    Duan, Rui-Sheng
    Sun, Shan-Mei
    Li, Yan-Bin
    JOURNAL OF NEUROIMMUNOLOGY, 2016, 298 : 138 - 145
  • [29] Longitudinal in vivo evaluation of retinal ganglion cell complex layer and dendrites in mice with experimental autoimmune encephalomyelitis
    Qian, Zhen
    Zheng, Ke
    Xu, Yanxuan
    Chen, Si
    Chen, Shaowan
    Liang, Jiajian
    Cao, Yingjie
    Ng, Tsz Kin
    Qiu, Kunliang
    EXPERIMENTAL EYE RESEARCH, 2023, 237
  • [30] The Role of Adenosine in γδ T-Cell Regulation of Th17 Responses in Experimental Autoimmune Uveitis
    Shao, Hui
    Kaplan, Henry J.
    Sun, Deming
    BIOMOLECULES, 2023, 13 (10)